Nature - Issue - nature.com science feeds

Oncolytic virus VG161 in refractory hepatocellular carcinoma

Nature, Published online: 19 March 2025; doi:10.1038/s41586-025-08717-5Results of a multicentre phase 1 clinical trial evaluating treatment with the engineered herpes simplex virus VG161 in advanced liver cancer indicate a good safety profile and promising efficacy.

Mar 19, 2025 - 17:46
 0
Oncolytic virus VG161 in refractory hepatocellular carcinoma

Nature, Published online: 19 March 2025; doi:10.1038/s41586-025-08717-5Results of a multicentre phase 1 clinical trial evaluating treatment with the engineered herpes simplex virus VG161 in advanced liver cancer indicate a good safety profile and promising efficacy.

Read More

Tags:

Previous Article

Mini-satellite paves the way for quantum messaging anywhere on Earth

Next Article

Why humans have puzzle-shaped cells

Related Posts

GluA2-containing AMPA receptors form a continuum of Ca<sup>2+</sup>-permeable channels

GluA2-containing AMPA receptors form a continuum of Ca<...

Mar 19, 2025  0

TIR1-produced cAMP as a second messenger in transcriptional auxin signalling

TIR1-produced cAMP as a second messenger in transcripti...

Mar 5, 2025  0

Daily briefing: ‘Devastating’ cuts to NIH grants blocked by legal challenge

Daily briefing: ‘Devastating’ cuts to NIH grants blocke...

Feb 12, 2025  0